Is Foundayo the Same as Oral Tirzepatide? What Patients Should Know

Foundayo is a new oral GLP-1 pill approved for chronic weight management from Eli Lilly, the same company behind Zepbound® and Mounjaro® — both of which contain tirzepatide. And with the same manufacturer, it’s easy to assume that Foundayo is tirzepatide as well.

However, Foundayo actually contains orforglipron, not tirzepatide. These are two different active ingredients with different mechanisms of action. So, let’s take a closer look at what this means.

‍

What Is Foundayo? And What Is Its Active Ingredient?

Foundayo is the brand name for orforglipron, a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in April 2026 for adults with obesity or overweight who have at least one weight-related medical condition, when used alongside a reduced-calorie diet and increased physical activity.

If GLP-1 receptor agonists sound unfamiliar, you may have heard of it in relation to semaglutide, another widely known GLP-1 medication. GLP-1 receptor agonists are a class of medications that mimic a natural gut hormone involved in appetite regulation, blood sugar control, and the speed at which food moves through your digestive system. By activating GLP-1 receptors in the brain, these medications are designed to mimic the action of the GLP-1 hormone involved in appetite regulation and feelings of fullness.

Unlike other oral GLP-1 options, Foundayo is taken as a once-daily tablet with no food or water restrictions. In other words, it can be taken any time of day.

‍

What Is Tirzepatide? And How Is It Different?

Tirzepatide is the active ingredient in two FDA-approved brand-name medications:

• Mounjaro® (approved for type 2 diabetes in adults and children ages 10 and older)
• Zepbound® (approved for weight loss and for obstructive sleep apnea in adults with obesity or overweight with a weight-related condition)

tirzepatide is a dual GLP-1/GIP receptor agonist, meaning it activates two gut hormone pathways rather than one. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone that, when activated alongside GLP-1, may support additional regulation of metabolism, appetite, and how the body handles fat.

However, tirzepatide is currently available only as a subcutaneous (under-the-skin) injection, administered once weekly. There is no FDA-approved oral version of tirzepatide at this time.

‍

Does a Tirzepatide Pill or “Zepbound® Pill” Exist?

As of the time of this publication, there is no FDA-approved oral version of tirzepatide. Zepbound® and Mounjaro® are both injectable-only formulations.

Again, the confusion often arises here because Eli Lilly manufactures both tirzepatide (Zepbound® and Mounjaro®) and orforglipron (Foundayo). And Foundayo’s approval as an oral GLP-1 weight-loss pill generated significant media coverage that sometimes blurs the two.

However, semaglutide, the active ingredient in Ozempic® and Wegovy®, is available in pill form; Rybelsus® is an oral semaglutide approved for type 2 diabetes (not weight loss, and it must be taken on an empty stomach roughly 30 minutes before food or drink), and an oral form of semaglutide for weight loss reached the market in late 2025 (the Wegovy® pill). 

If a provider or online source claims to offer “oral tirzepatide,” it's important to ask questions and discuss the product with a licensed healthcare provider. Either way, GLP-1 medications are only available through a prescription. In other words, it’s always important to discuss with a licensed healthcare provider what’s best for you.

‍

How Do Orforglipron and Tirzepatide Compare for Weight Loss?

No head-to-head trial between orforglipron and tirzepatide has been conducted, so cross-trial comparisons should be interpreted with caution. Individual results may vary based on starting weight, adherence, diet, activity level, and other health factors. A licensed provider is the appropriate person to evaluate which medication (or which type of treatment) may be most appropriate for your individual situation.

With that in mind, here is how the two compare in research:

• Orforglipron (Foundayo): In the 72-week ATTAIN-1 trial, participants taking the highest dose who stayed on treatment lost an average of about 12.4% of their body weight (about 27 pounds). Across all participants at that dose, including those who didn’t complete the trial, the average was about 11.1%.
• Tirzepatide (Zepbound®): In the 72-week SURMOUNT-1 trial, participants lost an average of roughly 16% to 22.5% of their baseline body weight, depending on dose, with the highest dose producing the largest reductions.

‍

Why the Difference in Efficacy Might Matter

Tirzepatide acts on two hunger-related pathways rather than one, which is thought to contribute to the higher average weight loss reported in its trials compared with medications that act on GLP-1 alone. It’s worth noting again that these figures come from separate studies, not a head-to-head trial, so they can’t be directly compared. On top of this, results may vary from person to person.

What matters more than the averages is what fits your situation. For some people, an oral option that may support weight loss without injections is appealing; for others, a medication with higher reported average weight loss may be a bigger consideration. This is a medical decision, not a personal preference, and a licensed provider is the right person to help you weigh the options.

‍

Orforglipron vs Tirzepatide: Key Differences at a Glance

Individual results may vary. This table reflects clinical trial data and approved indications, not guaranteed outcomes. Consult a licensed provider to determine which option may be appropriate for your health profile.

‍

What About Compounded Tirzepatide?

Compounded tirzepatide is an injectable medication, not a pill.

More specifically, compounded tirzepatide is a pharmacy-prepared version of the same active ingredient found in Zepbound®. But compounded medications are not FDA-approved and differ from commercially manufactured products. They’re prepared by a pharmacy for an individual patient according to a prescription from a licensed clinician. 

At Eden, we offer compounded tirzepatide injections through a provider-guided telehealth model for eligible adults. It all starts with a brief online intake. From there, we connect you with a licensed provider who evaluates you and your situation.

‍

How to Choose Between an Oral GLP-1 and an Injectable: What to Ask Your Provider

The right option ultimately depends on your health history, goals, and eligibility. If you’re weighing an oral GLP-1, such as orforglipron, against an injectable like tirzepatide, ask your provider the following questions:

• Based on my health history and goals, am I a candidate for an oral GLP-1 like orforglipron or an injectable like tirzepatide?
• How should the difference in average weight loss outcomes between these medications factor into a recommendation for me specifically?
• Are there any contraindications or drug interactions I should know about before starting either medication?
• If I'm needle-averse, is an oral GLP-1 a clinically appropriate alternative, or are there other considerations?
• What does ongoing monitoring and dose adjustment look like for each option?

If you’re not sure where you stand, a quick BMI calculator can provide more insight into your specific health situation. And if you’re exploring lower-dose approaches, it may be worth asking your provider about options such as GLP-1 microdosing as well.

Whichever direction you lean, GLP-1 medications, oral or injectable, require a prescription and should only be started under the supervision of a licensed provider.